Neoadjuvant and Adjuvant Treatment Considerations of ILC | Lobular Breast Cancer Event 2023

In this session, Megan Kruse, MD, Department of Hematology and Oncology, Cleveland Clinic presents “Neoadjuvant and Adjuvant Treatment Considerations of Lobular Breast Cancer.” To learn more about Dr. Kruse, please visit cle.clinic/3EOPjKH
Cleveland Clinic presented the 7th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure, a live educational multi-disciplinary summit that focused on the up-to-date reviews and treatment options for lobular breast cancer. This symposium was designed for practicing physicians and other practicing health care providers in oncology, surgery, radiation oncology, radiology, pathology and women’s health.
Learning objectives:
• Discuss diagnostic work up of lobular breast cancer.
• Review oncologic and plastic surgery approaches to lobular breast cancer.
• Describe approaches for radiation in the treatment of lobular breast cancer.
• Identify systemic treatment options for lobular breast cancer.
• Discuss challenges faced by lobular breast cancer survivors.
If you liked the video hit like and subscribe for more!
#clevelandclinic #medicaleducation #breastcancer #lobularbreastcancer

[@clevelandclinic]

Make a gift to Lobular Breast Cancer. Your support can help us to build a brighter future in women’s health through innovative research and educational opportunities. Ways to give: cle.clinic/3Q3JYFF

[@user-vu7vr7lb1j]

Thank you for this. I am an ILC survivor and always follow studies being done.

[@susanmacdonald5381]

Thanks to the Cleveland Clinic! The link above sends you to a dedicated fund to support research and treatment of Lobular Breast Cancer.

[@yorkiepeachygirlllc761]

Any information on the long term effectiveness of Tamoxifen on Invasive Lobular Cancer after a DMX for a post menopausal woman?

[@virginialaliberte2023]

This was extremely helpful! I have a patient with ILC high risk, had a recurrence on tamoxifen at 4 years and now 7 years on AI after that with no recurrence and her BCI showed exactly what you mentioned, that the recurrence score was high at 23%, but the predicted benefit of extended adjuvant endocrine therapy was NO, so we stopped it, because of adverse effects, but still wonder what else we could be doing to reduce that risk of a late recurrence. 😏

[@susanmacdonald5381]

Thanks to the Cleveland Clinic! The link above sends you to a dedicated fund to support research and treatment of Lobular Breast Cancer.